Literature DB >> 28508971

Short-term outcome and quality of life in kidney transplant recipient with monoclonal gammopathy.

Masaaki Yanishi1, Hiroyasu Tsukaguchi2, Takashi Yoshida3, Hisanori Taniguchi3, Kenji Yoshida3, Takao Mishima3, Yoshihiro Komai3, Kaneki Yasuda3, Masato Watanabe3, Motohiko Sugi3, Hidefumi Kinoshita3, Tadashi Matsuda3.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is the common pre-malignant B cell disorders with a general prevalence of 3-5 % at age over 50. Because of the potential malignant transformation and immune insufficiency, pre-transplant MGUS recipient should be carefully followed after allograft transplantation. The post-transplant prognosis and quality of life (QOL) in patient with MGUS have not yet been fully determined. The aim of this study is to evaluate function and pathology of the renal allograft and self-assessment QOL changes during 2 years after transplantation in our case of MGUS-bearing recipient. We here studied the clinical course and QOL improvement before and 20 months after transplant in a 56-year-old woman, who had pre-existing MGUS and underwent living donor kidney transplantation. After the renal allograft transplant, the patients maintained normal GFR and had neither acute rejections nor histologic evidence of renal injuries related to the monoclonal gammopathy on the protocol biopsy of 1 year post-transplant. During further 20 months follow-up, the pre-transplant MGUS remained uneventful without any hematologic abnormalities and other medical complications, i.e., infection. Evaluation of QOL using a self-assessment questionnaire showed significant improvement for physical and mental items on both 6 and 18 months post-transplant. The renal transplant thus successfully provided a greater satisfaction for the recipient on both physical and mental health aspects. Our observations suggest that renal transplantation is beneficial even in those who had pre-existing MGUS if managed and followed carefully, which ultimately could significantly improve the patient QOL.

Entities:  

Keywords:  Kidney transplantation; Monoclonal gammopathy; QOL

Year:  2016        PMID: 28508971      PMCID: PMC5413755          DOI: 10.1007/s13730-016-0218-1

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  17 in total

1.  Post kidney transplant quality of life prediction models.

Authors:  D K Hathaway; R P Winsett; C Johnson; E A Tolley; M Hartwig; J Milstead; M N Wicks; A O Gaber
Journal:  Clin Transplant       Date:  1998-06       Impact factor: 2.863

2.  Long-term follow-up of monoclonal gammopathy of undetermined significance in transplant patients.

Authors:  L Rostaing; A Modesto; M Abbal; D Durand
Journal:  Am J Nephrol       Date:  1994       Impact factor: 3.754

3.  Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.

Authors:  Victor H Jimenez-Zepeda; Raymond L Heilman; Rodney A Engel; Elizabeth J Carey; Ciara Freeman; Jorge Rakela; David C Mulligan; Rafael Fonseca; Alexander Keith Stewart
Journal:  Transplantation       Date:  2011-09-15       Impact factor: 4.939

4.  Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.

Authors:  Stefan Vítko; Raimund Margreiter; Willem Weimar; Jacques Dantal; Dirk Kuypers; Michael Winkler; Ole Øyen; Hendrik G Viljoen; Pavel Filiptsev; Sami Sadek; Yulan Li; Nathalie Cretin; Klemens Budde
Journal:  Am J Transplant       Date:  2005-10       Impact factor: 8.086

5.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

6.  Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance.

Authors:  Teresa E Goebel; Nicholas K Schiltz; Kenneth J Woodside; Aiswarya Chandran Pillai; Paolo F Caimi; Hillard M Lazarus; Siran M Koroukian; Erica L Campagnaro
Journal:  Clin Transplant       Date:  2015-08-20       Impact factor: 2.863

7.  Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Clara Cesana; Catherine Klersy; Luciana Barbarano; Anna Maria Nosari; Monica Crugnola; Ester Pungolino; Livio Gargantini; Simonetta Granata; Marina Valentini; Enrica Morra
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

Review 8.  Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Br J Haematol       Date:  2007-12       Impact factor: 6.998

Review 9.  Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.

Authors:  V Ram Peddi; Alexander Wiseman; Kenneth Chavin; Douglas Slakey
Journal:  Transplant Rev (Orlando)       Date:  2013-08-08       Impact factor: 3.943

10.  Kidney and pancreas transplantation in the United States, 1996-2005.

Authors:  K A Andreoni; K L Brayman; M K Guidinger; C M Sommers; R S Sung
Journal:  Am J Transplant       Date:  2007       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.